Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PARP1 | P09874 | 8/20 | 0.70 |
| ▸ | TP53 | P04637 | 2/20 | 0.46 |
| ▸ | MEN1 | O00255 | 2/20 | 0.41 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.41 |
| ▸ | POLB | P06746 | 1/20 | 0.40 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.40 |
| ▸ | USP2 | O75604 | 1/20 | 0.39 |
| ▸ | GAA | P10253 | 1/20 | 0.39 |
| ▸ | SMYD3 | Q9H7B4 | 1/20 | 0.39 |
| ▸ | THRB | P10828 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6309373 | 0.90 | PARP1 (0.76) | PARP1TP53MEN1KMT2APOLB | |
| SCHEMBL6305288 | 0.86 | PARP1 (0.88) | PARP1TP53POLBSMN1; SMN2SMYD3 | |
| SCHEMBL6302991 | 0.85 | PARP1 (0.90) | PARP1TP53POLBSMN1; SMN2USP2 | |
| SCHEMBL6998094 | 0.84 | PARP1 (0.72) | PARP1TP53MEN1KMT2APOLB | |
| SCHEMBL6998065 | 0.83 | PARP1 (0.75) | PARP1TP53SMYD3THRB | |
| SCHEMBL6992288 | 0.83 | PARP1 (0.75) | PARP1TP53MEN1KMT2APOLB | |
| SCHEMBL6310170 | 0.83 | PARP1 (0.95) | PARP1TP53POLBSMN1; SMN2SMYD3 | |
| SCHEMBL532477 | 0.83 | PARP1 (1.00) | PARP1TP53POLBSMN1; SMN2SMYD3 | |
| SCHEMBL7003151 | 0.83 | PARP1 (0.81) | PARP1TP53MEN1KMT2APOLB | |
| SCHEMBL6303081 | 0.82 | PARP1 (0.80) | PARP1TP53POLBSMN1; SMN2USP2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1015437-B1 | BENZOXAZINE AND BENZOTHIAZINE DERIVATIVES AND THEIR USE IN PHARMACEUTICALS | SCHERING AG (DE) | 2003-12-03 | — | — | EP | disclosed |
| US-6365736-B1 | TREATMENT OF NERVOUS SYSTEM DISORDERS, CARDIOVASCULAR DISORDERS AND FOR ACTIVITY AS NO-SYNTHASES (NOS) INHIBITORS. | SCHERING AKTIENGESELLSCHAFT (DE) | 2002-04-02 | — | — | US | disclosed |